Assessing health service satisfaction among users with substance use disorders within the municipalities in Norway.

BACKGROUND: The purpose of this study was to assess what is associated with health service satisfaction among adults with a substance use disorder receiving services provided within different municipalities in Norway. An additional aim was to examine demographic and municipality characteristics, mental health, and types of substance use associated with health service satisfaction. METHOD: A cross-sectional partial explorative study was executed in 2017 among 491 service users with substance use disorders from 20 randomly selected municipalities. The sample consisted of 70% males. The sample majority were single and unemployed, and their main sources of healthcare were the general practitioner (78%), The Norwegian Labor and Welfare Administration (72%), and addiction counsellors (62%). RESULTS: Overall satisfaction was negatively associated with age, size of municipality, Global Severity Index (GSI) and illicit substance use during the last 12 months. Satisfaction with practical help, such as housing, economy, work and education, was negatively associated with GSI and positively associated with onset of first alcohol intoxication. Satisfaction with personnel was positively associated with onset of first alcohol intoxication and negatively associated with municipality size, GSI and illicit use the last 12 months. The results showed that more than half of the respondents (54%) to a large or great extent were satisfied with the overall services provided. The services they were less satisfied with were related to housing, economy, getting started with exercise and establishing a social network. CONCLUSION: The results show areas associated with satisfaction and domains where the municipalities can improve their services to meet the users' needs and increase service satisfaction.

Convergent validity of the ASAM criteria in co-occurring disorders.

OBJECTIVE: The complexity of substance use and psychiatric disorders demands thorough assessment of patients for integrated services. We tested the convergent validity of the software version of the American Society of Addiction Medicine (ASAM) second edition-revised criteria for patient placement by examining the software's ability to discriminate based on a variety of demographic and clinical factors. METHODS: This prospective naturalistic multi-site study examined the software's assignment of patients to three types of treatment (addiction only services, dual diagnosis capable, and dual diagnosis enhanced) and whether these assignments indicated an ability to discriminate between patients with and without dual diagnosis based on clinical characteristics and severity. Ten addiction treatment clinics spanning three counties participated, and both patients and ASAM assessors were kept blind to the ASAM recommendation. Patients were assigned to their respective treatment options based on routine assessment by clinicians at intake, which they had in addition to the ASAM interview. Three months after treatment initiation a follow-up interview with ASAM was conducted. RESULTS: There were 261 patients in the study, 96 (36.7%) were assigned to addiction only services, 42 (16.1%) to dual diagnosis capable, and 123 (47.1%) to dual diagnosis enhanced. Patients assigned to the two dual diagnosis groups were significantly more likely to be younger and have fewer years of work than other patients. There were significant differences in history of inpatient and outpatient psychiatric treatment across groups. For example, a larger percentage of those in addiction only services had never been in inpatient treatment, while more of those in the two dual diagnosis groups had three or more inpatient stays. Despite similar alcohol and drug severity scores, patients recommended by the software for dual diagnosis enhanced programs showed a gradient of significantly higher psychiatric (p <.001), legal (p <.04), and family (p <.001) Addiction Severity Index composite scores at baseline than patients in dual diagnosis capable and addiction only services. CONCLUSIONS: RESULTS show a high prevalence of co-occurring program recommendations with statistically significant and clinically meaningful differences between patient groups. The convergent validity of the revised version of ASAM Criteria Software is supported by these results.

Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations.

BACKGROUND: Methadone and buprenorphine are widely used in the treatment of opioid addiction. Some study results suggest that methadone can be associated with QT interval prolongation and torsades de pointes ventricular arrhythmias, whereas no such risk has been observed for buprenorphine. The aim of this study is to determine the risk of corrected QT interval (QTc) increase among patients treated with these medications in an opioid maintenance treatment (OMT) programme, and to study possible associations between QTc changes and serum concentrations of methadone or buprenorphine. METHODS: Eighty patients enrolled in the OMT programme were followed after start of treatment with methadone (n=45) or buprenorphine (n=35). QTc interval was assessed by electrocardiography (ECG) at baseline and after 1 month (n=79) and 6 months (n=66) in the OMT programme. Blood samples were obtained for the analysis of serum concentrations of buprenorphine, (R)-methadone, (S)-methadone and total methadone. RESULTS: No patients had QTc prolongation (defined as a QTc value above 450 ms) at baseline or after 1 or 6 months. When analysed in a linear mixed effects model, QTc was not associated with the serum concentrations of buprenorphine or methadone. However, low serum potassium levels increased QTc significantly. CONCLUSIONS: These results support and extend previous findings that treatment with methadone in modest doses (i.e. below 100mg/d) is not associated with clinically significant QTc increases, and that buprenorphine in commonly used doses is a suitable alternative to methadone with regard to the risk of QTc prolongation.